Core Concepts
Guideline-concordant care is crucial for improving overall survival in inflammatory breast cancer patients.
Abstract
The study presented at the San Antonio Breast Cancer Symposium highlighted the importance of guideline-concordant care in improving overall survival rates for patients with inflammatory breast cancer. The majority of patients, especially Black and Asian individuals, did not receive the recommended treatment, leading to disparities in survival outcomes. The study emphasized the need to address barriers to guideline-concordant care to enhance patient outcomes and reduce racial disparities in survival rates.
Key Highlights:
- Guideline-concordant care linked to improved survival in inflammatory breast cancer.
- Black women had the lowest overall survival without guideline-concordant care.
- Only about one third of patients received guideline-concordant treatment.
- Timely receipt of care positively impacted overall survival, particularly for Black patients with triple-negative disease.
Stats
Most patients (88%) did not start neoadjuvant chemotherapy within 60 days of diagnosis.
Black and Asian patients were less likely than White patients to start chemotherapy within 60 days (odds ratio [OR] 0.54 and 0.51, respectively; P < .001).
Patients treated between 2014 and 2018 were less likely to receive guideline-concordant treatment than patients treated between 2010 and 2013 (OR, 0.63; P <.001).
Receiving guideline-concordant care and being privately insured were both positively associated with improved overall survival (OR, 0.75 and 0.62, respectively; P < .001).
Quotes
"Improving guideline-concordant care will improve outcomes for all patients with inflammatory breast cancer." - Kathryn Hudson, MD